Short CommunicationPATRIOT: A phase I study to assess the tolerability, safety and biological effects of a specific ataxia telangiectasia and Rad3-related (ATR) inhibitor (AZD6738) as a single agent and in combination with palliative radiation therapy in patients with solid tumours
Under a Creative Commons license
open access
Keywords
Phase I
Radiosensitization
ATR inhibition
DNA damage response
Clinical trial
Cited by (0)
- 1
These Authors contributed equally to this work.
© 2018 The Authors. Published by Elsevier B.V. on behalf of European Society for Radiotherapy and Oncology.